Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT04176718Phase 2Active, not recruiting
- Start
- May 2020
- Primary completion
- May 2027
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM). Started May 2020; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04176718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176718.